Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2759-2765

  Roth, Wilfried ^a   Isenmann, Stefan ^a   Nakamura, Mitsutoshi ^b   Platten, Michael ^a,b   Wick, Wolfgang ^a   Bähr, Mathias ^a   Ohgaki, Hiroko ^b   Ashkenazi, Avi ^c   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL RECEPTOR; DECOY RECEPTOR 3; FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CHEMOTAXIS; DISEASE PROGRESSION; FAS LIGAND PROTEIN; GLIOMA; HUMANS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICROGLIA; RATS; RATS, INBRED F344; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035866822     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chemotherapy and immunotherapy of malignant glioma: Molecular mechanisms and clinical perspectives
2. The failure of current immunotherapy for malignant glioma
3. Apoptosis by death factor
4. Antitumor effect of locally produced CD95 ligand
5. Inhibition of death receptor signals by cellular FLIP
6. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
7. The inhibitor of death receptor signaling
8. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy
9. Soluble CD95 (Fas/APO-1) in malignant glioma: (no) Implications for CD95-based immunotherapy?
10. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
11. Overexpression of M68/DeR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
12. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis
13. Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics
14. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
15. Monokine production by microglial cell clones
16. Bag-1 and bcl-2 gene transfer in malignant glioma: Modulation of cell cycle regulation and apoptosis
17. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
18. Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat
19. Secreted Frizzled related proteins inhibit motility and promote growth of malignant glioma cells
20. APO2 ligand: A novel lethal weapon against malignant glioma?
21. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
22. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells
23. CD95 ligand: Lethal weapon against malignant glioma?
24. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors
25. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
26. Expression of Fas/APO-1 during the progression of astrocytomas
27. Death receptors: Signaling and modulation
28. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
29. Preferential expression of Fas/APOI (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme
30. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas
31. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
32. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains
33. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
34. Chemotactic activity of soluble Fas ligand against phagocytes
35. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand